Tectonic Therapeutic (TECX) said late Thursday that its lead asset TX45 for the potential treatment of group 2 pulmonary hypertension in heart failure with preserved ejection fraction showed "minimal" adverse events in a phase 1a clinical trial.

TX45 was well-tolerated and showed a "favorable" pharmacokinetic and pharmacodynamic relationship that was used to identify doses for phase 2 clinical trial, the company said.

"These topline phase 1a findings for TX45 validate the preliminary data previously presented at lower doses, and we look forward to sharing the full trial results at the AHA Scientific Sessions later this year," Tectonic Chief Executive Alise Reicin said.

Price: 19.81, Change: +0.01, Percent Change: +0.05